No Data
No Data
Huaren Pharmaceutical (300110.SZ): Wholly-owned subsidiary has obtained the drug registration certificate for hydrochloride deoxycorticosterone injection.
On June 9, Gelonghui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (referred to as "Anhui Hengxing Pharmaceutical") recently received the "Drug Registration Certificate" approved and issued by the National Medical Products Administration for "Hydrochloride Deoxycorticosterone Injection." This injection is used to treat clinical hypotension caused by vasodilation during anesthesia and is classified as a type B item in the national medical insurance. According to Statistics data, the domestic hospital sales of Hydrochloride Deoxycorticosterone Injection in 2024 is estimated to be 0.119 billion yuan.
Express News | Huaren Pharmaceutical: The company and its subsidiaries' products have been selected for interprovincial alliance bulk procurement of chemical drugs.
Express News | Huaren Pharmaceutical: Shareholder Huaren Century Group intends to reduce its shareholding by no more than 1% of the company's shares.
Huaren Pharmaceutical Gets Medical Device Registration for Wound Dressing Product
Express News | Huaren Pharmaceutical: The subsidiary obtained the medical instruments registration certificate.
Huaren Pharmaceutical: Report for the first quarter of 2025